Arrowstreet Capital
CSTL icon

Arrowstreet Capital’s Castle Biosciences CSTL Stock Holding History

Arrowstreet Capital’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$666K Buy
27,142
+20,113
+286% +$659K ﹤0.01% 1620
2025
Q4 		$273K Buy
+7,029
New +$227K ﹤0.01% 1747
2025
Q1 		– Sell
-28,903
Closed -$770K – 1846
2024
Q4 		$770K Buy
+28,903
New +$880K ﹤0.01% 1506

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arrowstreet Capital's CSTL Position: Q1 2026 in Review

Arrowstreet Capital increased its Castle Biosciences (CSTL) stake by 286% in Q1 2026, buying an estimated $659K and bringing the position to 27,142 shares worth $666K. The position accounts for ﹤0.01% of the portfolio, ranked #1620.

Arrowstreet Capital first reported a position in CSTL in Q4 2024 and has held it in 3 quarters since. The position peaked at $770K in Q4 2024. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Arrowstreet Capital held 27,142 shares of Castle Biosciences worth $666K as of Q1 2026.
  • Arrowstreet Capital bought 20,113 Castle Biosciences shares in Q1 2026, an estimated $659K.
  • Castle Biosciences made up ﹤0.01% of Arrowstreet Capital's portfolio in Q1 2026, its #1620 holding.
  • Arrowstreet Capital first reported a position in Castle Biosciences in Q4 2024 and has held it in 3 quarters since.
  • Arrowstreet Capital's Castle Biosciences position peaked at $770K in Q4 2024.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.